Indexado em
  • Banco de Dados de Periódicos Acadêmicos
  • Genamics JournalSeek
  • Chaves Acadêmicas
  • JournalTOCs
  • Infraestrutura Nacional de Conhecimento da China (CNKI)
  • Scimago
  • Acesso à pesquisa on-line global em agricultura (AGORA)
  • Biblioteca de periódicos eletrônicos
  • RefSeek
  • Diretório de Indexação de Periódicos de Pesquisa (DRJI)
  • Universidade de Hamdard
  • EBSCO AZ
  • OCLC- WorldCat
  • Catálogo online SWB
  • Biblioteca Virtual de Biologia (vifabio)
  • publons
  • MIAR
  • Comissão de Bolsas Universitárias
  • Fundação de Genebra para Educação e Pesquisa Médica
  • Euro Pub
  • Google Scholar
Compartilhe esta página
Folheto de jornal
Flyer image

Abstrato

Denovo Designing, Virtual Screening and Lead Optimization of Potential Drug Candidate for Herpes Disease

Monica Sharma, Puneet Rawat and Ankita Mehta

Herpes simplex virus (HSV1, HSV 2) is a neurotropic and neuroinvasive virus which becomes latent and causes a lifelong infection. HSV-1 and 2 produce infected cell protein (ICP)-47 against MHC class I antigen presentation pathway by inhibiting the transporter associated with antigen processing (TAP). ICP 47 is also responsible for evasive nature of HSV in human immune system. Currently available antiviral drugs and vaccines only slowdowns the infection but it does not cure the infection. In present study, we have in silico designed a potential drug candidate against HSV ICP-47 target through de-novo pathway using eLEA3D. The derived ligand docked with the natural viral receptor ICP-47 showed the binding affinity of -4.07, but it was found toxic in FAF DRUG online ADMET tool, due to presence of high risk imine group. Further manual optimization led to generation of many bioisosteres and final lead structure showed no toxicity and a high binding affinity of -7.53. Our designed lead can act as a potential therapeutic compound against HSV.